Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells

Ewing Sarcoma (ES) is a highly aggressive bone and soft tissue childhood cancer. The development of resistance to chemotherapy is common and remains the main cause of treatment failure. We herein evaluated the expression of genes associated with chemotherapy resistance in ES cell lines. A set of gen...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2018-06, Vol.8 (6), p.719-724
Main Authors: Horbach, Leonardo, Sinigaglia, Marialva, Da Silva, Camila Alves, Olguins, Danielly Brufatto, Gregianin, Lauro José, Brunetto, Algemir Lunardi, Brunetto, André Tesainer, Roesler, Rafael, De Farias, Caroline Brunetto
Format: Article
Language:English
Subjects:
Apoptosis
Cancer genetics
Cancer research
Cancer therapies
Cell cycle
Cell growth
Chemotherapy
Deoxyribonucleic acid
DNA
Drug dosages
Drug resistance
Drug therapy
Ewing's sarcoma
Ewings sarcoma
Experiments
Gene expression
Genetic aspects
Oncology
Polymerase chain reaction
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ewing Sarcoma (ES) is a highly aggressive bone and soft tissue childhood cancer. The development of resistance to chemotherapy is common and remains the main cause of treatment failure. We herein evaluated the expression of genes associated with chemotherapy resistance in ES cell lines. A set of genes (CCAR1, TUBA1A, POLDIP2, SMARCA4 and SMARCB1) was data-mined for resistance against doxorubicin and vincristine, which are the standard drugs used in the treatment of patients with ES. The expression of each gene in SK-ES-1 ES cells was reported before and after exposure to a drug resistance-inducing protocol. There was a significant downregulation of CCAR1 and TUBA1A in doxorubicin-resistant cells, with low expression of TUBA1A in vincristine-resistant cells. By contrast, POLDIP2 was significantly upregulated in cells resistant to either drug, and the expression of the SMARCB1 and SMARCA4 genes was upregulated in doxorubicin-resistant cells. These findings indicate that resistance to specific chemotherapeutic agents was accompanied by differential changes in gene expression in ES tumors.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2018.1608